Paclitaxel treatment may also be beneficial for immunotherapy in ovarian cancer, as it has been shown to elevate the levels of CD8+ T cell infiltration in an ovarian cancer mouse model through increasing expression of both MHC-I and PD-L1 (93). The gene discussed is CD274; the disease is ovarian cancer.